Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Express Scripts
Harvard Business School
Fish and Richardson

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,071,130

« Back to Dashboard

Which drugs does patent 8,071,130 protect, and when does it expire?

Patent 8,071,130 protects DUETACT and is included in one NDA. There has been one Paragraph IV challenge on Duetact.

This patent has twenty-six patent family members in twenty-three countries.

Summary for Patent: 8,071,130

Title:Solid preparation
Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from "a solid preparation containing only an insulin sensitizer as an active ingredient". The solid preparation comprises "a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol" and "a part containing an active ingredient other than an insulin sensitizer".
Inventor(s): Kiyoshima; Kenichiro (Osaka, JP), Nakamura; Kenji (Osaka, JP), Kawano; Tetsuya (Osaka, JP), Misaki; Masafumi (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/086,700
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-001Jul 28, 2006ABRXYesYes► Subscribe► SubscribeY
Takeda Pharms Usa
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-002Jul 28, 2006ABRXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,071,130

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2005-370375Dec 22, 2005
PCT Information
PCT FiledDecember 21, 2006PCT Application Number:PCT/JP2006/326169
PCT Publication Date:June 28, 2007PCT Publication Number: WO2007/072992

International Patent Family for Patent: 8,071,130

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20083104► Subscribe
Malaysia149306► Subscribe
Morocco30061► Subscribe
South Korea20080080126► Subscribe
Japan5179363► Subscribe
Japan2009520681► Subscribe
Israel191774► Subscribe
CroatiaP20160679► Subscribe
Georgia, Republic ofP20115245► Subscribe
Spain2576258► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
Federal Trade Commission
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus